Loading organizations...
We’re building foundation models for the human cell, harnessing AI to usher in a new era of human repair.
Somite has raised $61.8M across 3 funding rounds.
Somite has raised $61.8M in total across 3 funding rounds.
Somite has raised $61.8M in total across 3 funding rounds.
Somite's investors include Khosla Ventures, Boldstart Ventures, DST Global, Electric Capital, Founders Fund, Han Hua, Lux Capital, Quiet Capital, Anthony Pompliano, Eric Wu, Othman Laraki, Steve Lee.
Somite has raised $61.8M across 3 funding rounds. Most recently, it raised $47.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $47M Series A | Khosla Ventures | Boldstart Ventures, DST Global, Electric Capital, Founders Fund, HAN HUA, LUX Capital, Quiet Capital, Anthony Pompliano, Eric WU, Othman Laraki, Steve LEE, Fidji Simo, Martin Chavez, Ajinomoto Group Ventures, Chan Zuckerberg Initiative, Fusion Fund, Harpoon Ventures, Pitango HealthTech, SciFi VC, TechAviv | Announced |
| Sep 9, 2024 | $4.8M Seed Plus | Astellas Venture Management, Daphne CHE | Kendra Harris, Nachum Shamir | Announced |
| Apr 1, 2024 | $10M Seed | Yaron Samid | Boldstart Ventures, Micha Y. Breakstone, Lerer Hippeau, Next Coast Ventures, Texas Venture Partners, Trust Ventures | Announced |
Somite is a technology company specializing in AI-driven foundation models to accelerate and scale the development of human cell therapies, aiming to make these therapies faster, more reliable, and broadly accessible to patients[1][2]. Their flagship product, DeltaStem, leverages proprietary AI and capsule technology to generate vast cell state transition data, enabling a 1000x efficiency improvement over traditional methods. Somite primarily serves biotech and medical researchers focused on cell replacement therapies for diseases such as Type 1 Diabetes, muscular disorders, orthopedic conditions, and blood diseases[1].
Founded by AI entrepreneur Dr. Micha Breakstone and MIT AI expert Dr. Jonathan Rosenfeld, alongside leading scientific co-founders from Harvard Medical School and the University of Washington, Somite emerged from the convergence of AI scaling breakthroughs and the urgent need to improve cell therapy development[1][2]. Early traction includes a successful $47 million Series A funding round led by Khosla Ventures and participation from prominent investors like the Chan Zuckerberg Initiative and SciFi Ventures, positioning Somite to accelerate its therapeutic programs and platform development[1].
Somite rides the wave of AI integration into biotech, a trend transforming drug discovery and regenerative medicine. The timing is critical as traditional cell therapies face challenges of high cost, slow development, and unpredictability. By harnessing AI foundation models, Somite addresses these bottlenecks, potentially reshaping the cell therapy market and enabling scalable, personalized medicine. This aligns with broader market forces emphasizing precision health, AI-driven innovation, and the growing demand for effective treatments for chronic and degenerative diseases[1].
Somite is poised to be a pioneer in the AI-powered cell therapy space, with its DeltaStem platform setting new standards for speed and scalability. Future growth will likely be shaped by advances in AI model capabilities, expanding therapeutic targets, and increasing partnerships with pharmaceutical and biotech companies. As AI continues to revolutionize life sciences, Somite’s influence could extend beyond cell therapy into broader regenerative medicine and human repair technologies, fulfilling its mission to transform millions of lives[1][2].
